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Background: The National Institute for Health and Clinical Excellence (NICE) COPD 2004 guide-
lines recommend:
* COPD patients who smoke should be encouraged to stop at every opportunity;
) Inhaled corticosteroid should be used only among patients with moderate to severe COPD;
) Pharmacists should identify smokers and provide smoking cessation advice.
The community pharmacy contract requires pharmacists to review patients’ medications,
creating an opportunity for reviewing the prescribing of inhaled corticosteroids in COPD.
The survey explored the degree to which community pharmacists in North West England
identify and provide advice to smokers and assess prescribed inhaled corticosteroids among
COPD patients.
Methods: A self-completion questionnaire was sent to 2080 community pharmacists from the
2005 pharmacist census database.
Results: Of the 1051 (50.5%) respondants, 37.1% mentioned COPD as a risk from smoking most
or every time and 54.5% sometimes or rarely, and 19.6% routinely asked about smoking status
when dispensing COPD medication. Pharmacists with more than 20 years experience were
more likely to have read the Guideline compared to pharmacists with 10 years or less (OR:
1.54; 95% CI: 1.13 to 2.10). Pharmacists who had read the NICE Guideline (46.8%) were around)161 275 5206 ; fax: þ44 (0)161 306 0693.
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Are pharmacists reducing COPD’S 231twice as likely to mention COPD as a risk of smoking, ask about COPD if inhaled corticosteroids
were dispensed and ask about smoking routinely if COPD medication was dispensed. (p<0.005).
Conclusion: The NICE guidelines on COPD encourage community pharmacists to carry out
smoking cessation and educational interventions, but further support is needed.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
It is estimated that the number of patients suffering from
chronic obstructive pulmonary disease (COPD) in England
and Wales, including those who are undiagnosed, is as high
as 3 million.1 Smoking is recognised as the most important
causal factor for COPD, and provokes exacerbations which
are distressing and disruptive events for the sufferer and
their carers, and are associated with increased hospital
admissions and reduced survival.2,3 Smoking cessation is the
most significant component of COPD management,2,4e6 and
the UK National Institute for Clinical Excellence (NICE)
COPD Guidelines 2004 and 2010 recommend that all COPD
patients who smoke should be encouraged to stop at every
opportunity.7,8
The UK Department of Health’s A Vision for Pharmacy in
the new NHS and Choosing health through pharmacy -
a programme for pharmaceutical public health, recom-
mends that pharmacists, as health care professionals in the
community, should promote healthy lifestyles including
offering smoking cessation interventions.9,10 The NICE
report Helping smokers to stop: advice for pharmacists in
England suggests that pharmacists should advise people
how to stop smoking, provide information on supply of
cessation medications and some should provide smoking
cessation services.11
In patients with severe COPD use of inhaled corticoste-
roids (ICS) reduces the frequency of exacerbations.
Therefore current advice is that their use should be limited
to that group.7,8 However, the use of ICS among COPD
patients exceeds the expected rate, suggesting that many
patients with mild COPD are treated with ICS.12,13 This
study was completed before the guidelines were updated
by NICE in 2010.
The ‘Medicines use review (MUR) and prescription
intervention service’, part of the new UK community
pharmacy contract, was introduced into health services in
England and Wales in 2005. The focus of the contractual
framework is not primariliy on diagnosis, but on optimising
therapies prescribed by the GP. It requires community
pharmacists to review patients’ medications for identified
conditions, such as respiratory disease, and send reports to
GPs on any suggested changes to the patients’ prescrip-
tions.14 As part of the MUR process, community pharmacists
could identify COPD patients and conduct reviews when
dispensing ICS in order to identify COPD patients who may
not benefit from this treatment.
This study aimed to explore COPD management among
community pharmacists working in North West England in
relation to identifying smokers and promoting smoking
cessation, and reviewing the prescribing of ICS. We also
wished to explore if the pharmacist confirmed wither the
patient had COPD or asthma.Methods
Community pharmacists with registered addresses in North
West England were identified from the Centre for Pharma-
ceutical Sciences, University of Manchester database,
which stores data from Royal Pharmaceutical Society of
Great Britain (RPSGB) 2005 census of pharmacists.15 The
database includes all pharmacists working in the commu-
nity, hospital, industry and academia in full-time, part-time
or locum employment.
A self-completion questionnaire (available on request),
which was piloted with two community pharmacists outside
the North West region, was sent in MarcheApril, 2007. The
questionnaire aimed to elicit information on the following:
 Years of practising as a community pharmacist
 Awareness and reading of NICE guideline Management
of COPD in adults in primary and secondary care (2004)
 Interest in improving knowledge about COPD
 Practice in asking about smoking status when dispensing
COPD medications eg ICS
 Practice in mentioning COPD as being associated with
smoking
 Practice in making COPD patients aware of risks from
smoking
 Practice in asking about patient’s diagnosis of COPD or
asthma when dispensing inhaled corticosteroids
A reminder letter and a second copy of the questionnaire
were sent to non-responders. The details of the survey are
as explained elsewhere.16
Data were analysed in Microsoft Excel 2003 and using
Open-Epi.17
The survey was regarded as a service evaluation by the
University Research Ethics Committee.Results
Questionnaires were sent to 2273 pharmacists. However, 193
of those had died, retired, moved outside the North West
England region or were no longer practising and hence were
excluded fromthe study. 1051out of 2080eligible community
pharmacists practising in the Region completed and returned
the questionnaire giving a response rate of 50.5%.
The questionnaires were received from community
pharmacists with varying degrees of experience: 286
(27.2%) with 0e10 years, 236 (22.5%) with 11e20 and 458
(43.6%) with more than 20 years; 71 (6.7%) pharmacists did
not report the number of years they had been practising as
a community pharmacist.
Of 1047 pharmacists who responded to this question, 929
(88.7%; 95% confidence interval 86.7e90.5%) were aware of
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Secondary Care (2004), and 490 (46.8%; 43.8e49.8%)
reported that they had read it. Compared to the pharma-
cists with 10 years or less experience, those with more than
20 years experience were more likely to have read the
Guideline (odds ratio (OR) 1.54; 1.13e2.10).
More than 80% of pharmacists felt that they needed to
improve their knowledge about COPD management
(n Z 848; Table 1); 90.7% thought that training in COPD
management would be beneficial (n Z 953; Table 1).
In an open question pharmacists were asked to list the
specific types of consultations where they would ask about
smoking status. Of the 579 (55.1%) who responded, 62
(10.7%; 8.4e13.4%) reported asking about smoking status if
the consultation or prescription was for COPD, compared to
115 (19.9%; 16.8e23.3%) if it was for asthma. A further 264
(45.6%; 41.6e49.7%) reported asking during consultations
for respiratory symptoms, which is very likely to include
asthma and COPD consultations as well as others.
When pharmacists were asked whether they routinely
asked about the smoking status of their clients when
dispensing COPD medication, 203 (19.6%; 17.3e22.1%) of
the 1037 who responded to this question stated that they
did, and 189 of those (93.1%; 89.0e96.0%) stated in the
following question that they also educated smokers about
the additional risk of continuing smoking. Of the 834
(80.4%; 77.9e82.8%) community pharmacists who did not
ask about smoking status routinely when dispensing COPD
medication, 30 (3.6%; 2.5e5.0%) nevertheless reported that
they did provide education about smoking. Therefore,
21.3% of all responders educated their clients receiving
COPD medication about the additional risk of continuing to
smoke. Participants who had been in practice for more than
20 years were more likely to ask about smoking status of
their clients than those with 10 years or less experience;
however, the odds ratio was not statistically significant (OR
1.33; 0.91e1.95).
Overall, 387 (37.1%) of the pharmacists reported that
they mentioned COPD ‘most times’ or ‘every time’ as being
a risk from smoking; 568 (54.5%) mentioned it ‘sometimes’
or ‘rarely’.
In response to a prompted question, 87 (8.3%) commu-
nity pharmacists reported that they asked ‘most times’ or
‘every time’ whether the patient was diagnosed with COPD
or asthma when dispensing ICS. A further 709 (68.0%) also
asked, but only ‘sometimes’ or ‘rarely’. The community
pharmacists who had read the NICE Guideline were around
twice as likely to mention COPD as a risk from smoking, ask
the patient’s diagnosis if ICS were dispensed, and ask about
smoking routinely if COPD medication was dispensed,
compared to those who had not read the guidelines
(p < 0.005; Table 2).Table 1 Community pharmacists’ opinions on improving their k
Need to improve knowledge on COPD management
(1046 responders to this question)
Training would be beneficial (1041 responders to this question)Discussion
This survey found high levels of awareness of the NICE COPD
guidelines among community pharmacists, though less than
half had read the guidelines. Around a fifth reported usually
discussing smoking when dispensing COPD medication, with
most of these pharmacists also reporting that they
educated COPD patients who are smokers about the risks of
smoking. A larger proportion (40%) reported that they drew
smokers’ attention to the risks of COPD due to smoking.
Only 8% of pharmacists reported that they asked most times
about the diagnosis when dispensing COPD medications. It
therefore seems unlikely that a full MUR, including an
assessment of COPD severity, occurs with very high
frequency.
Strengths of the study are that it included a large
number of subjects from a clearly defined population of
pharmacists. Weaknesses include the moderate response
rate, the restriction to pharmacists from the North West of
England (potentially affecting generalisability). Due to the
low response rate, it is possible that there was some
selection bias if response was higher among different
practice types e.g. rural vs urban practices, or that the
responding pharmacists had systematically different prac-
tice from non-responders.
We found a link between reading of the NICE COPD
guidelines and the frequency of asking about smoking,
educating smokers about the risks of COPD and asking
about the diagnosis among patients dispensed COPD
medications (Table 2). However, due to the cross-sectional
nature of the data, the direction of causality for these
associations is not clear, and it may be that pharmacists
who carry out these best practice activities are also more
inclined to read NICE guidelines, rather than the alterna-
tive explanation that reading the guidelines resulting in
changed behaviours.
Another potential explanation is that the association of
having read the NICE guidelines with increased imple-
mentation of recommended practices like asking about
smoking status could be due to confounding factors. These
could include whether the pharmacist was in a group of
practices rather than being an independent practice (group
practices might have specific training schedules and poli-
cies), and also years of practice and levels of qualifications
and training (in general or in COPD management in partic-
ular). In order to keep the questionnaire short, we did not
ask about these factors.
It should be noted that the questionnaire was designed
based on the 2004 version of the NICE guideline: this was
updated in 2010. The guidance on smoking is unchanged
although the recommendations around the use of cortico-
steroids in COPD were modified, however, the changes didnowledge further.
Yes n % (95% CI) No n % (95% CI)
848
81.1 (78.6e83.4)
198
18.9 (16.6e21.4)
953
91.5 (89.7e93.1)
88
8.5 (6.9e10.3)
Table 2 Relationship between reading the COPD Guideline and compliance with the recommendations among community
pharmacists.
Read NICE COPD Guideline p-value
Yes % (95% CI) No % (95% CI)
Ask about smoking routinely if COPD
medication dispensed (n Z 1036)
27.2 (23.4e31.4) 12.9 (10.3e15.9) <0.001 (<0.0001)
Ask at least sometimes whether COPD/Asthma
diagnosed if inhaled corticosteroids dispensed (n Z 1041)
11.0 (8.5e14.2) 6.0 (4.3e8.3) <0.001 (Z0.0002)
Mention COPD at least sometimes as a risk from smoking
(n Z 1042)
49.5 (45.1e53.9) 22.1 (18.7e25.8) <0.001 (<0.0001)
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pretation of the results.
Smoking cessation is considered as one of the main roles
of pharmacists, due to the community pharmacists’ regular
contact with large numbers of people every day.11 Although
NICE COPD Guideline recommends that COPD patients who
smoke are encouraged to stop “at every opportunity”, and
the Guideline was claimed to be read by almost half of the
pharmacists, only around one in five (21.3%) stated that
they educate smokers about the risks of smoking when
dispensing COPD medication.
The finding that reading the COPD Guideline was asso-
ciated with increased likelihood of asking about smoking
status, mentioning COPD as a risk from smoking, and asking
about the diagnosis among patients dispensed COPD medi-
cations suggests that the NICE Guidelines have had positive
effects on practice. However, as mentioned above the
direction of causality is not clear, and it is also possible that
the association is due to confounding factors.
The role of community pharmacists in chronic disease
management has long been discussed and the medication
review is seen as one of the key activities where they can
make a contribution.18 A review of the MUR service showed
that respiratory diseases were the most commonly targeted
condition by MURs, 38.7%, as stated by pharmacy leads in
primary care organisations.19 The study also showed that
38.0% of pharmacists provided MUR to their patients in the
first year of the service and uptake was found to be
increasing.19,20 It is suggested that an average community
pharmacy serves 78 COPD patients.18 The MUR service is
certainly an important opportunity to identify inappro-
priate use of ICS but even those pharmacists who don’t
offer a full MUR could review ICS use in patients when
dispensing them. However, in our study only 8.3% of
community pharmacists reported that they ask about the
diagnosis most times or every time and 68.0% sometimes or
rarely when dispensing this group of medications. This
suggests that further work is required to identify COPD
patients who could benefit from a MUR.
In our study we found a significant association between
pharmacists’ experience, and them having read the NICE
guidance on the treatment of COPD (2004). A study pub-
lished in 2008 from the same population noted the opposite
association, that is, that more experienced pharmacists
were less likely to be aware of the NICE document ‘Helping
smokers to stop; advice for pharmacists in England’ (2005).
This could be explained by the novelty of the COPD
guidelines versus the plethora of information on smokingcessation. However, we were not able to test the validity of
this observation.
The majority of community pharmacists wanted to learn
more about COPD management (81.1%). This suggests that
a training programme would have a high uptake. Interest-
ingly, those who had not read the Guideline were more
likely to be interested in improving their knowledge than
those who had read them (87.8% vs 72.2%).
Conclusion and recommendations
The results from this study suggest that further work over
and above the distribution of current NICE guidelines is
required to encourage and support community pharmacists
to carry out smoking cessation and educational interven-
tions, and to review medication use among COPD patients
prescribed ICS.
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